Paper Details

  1. Home
  2. Paper Details

Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis.

Author: AdamicovaK, KajoK, KubatkaP, NosalovaG, OstatnikovaD, SadlonovaJ, SadlonovaV

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the side effects of the aromatase inhibitor anastrozole in preventing N-methyl-N-nitrosourea-induced premenopausal mammary carcinogenesis in female Sprague-Dawley rats. The study mimicked the situation in healthy, high-risk premenopausal women from the perspective of breast cancer development. The animals received anastrozole in their food throughout the experiment, with Group 1 (control) receiving food without anastrozole, Group 2 receiving 0.05 mg/1 kg of food (ANA 0.05), and Group 3 receiving 0.5 mg/1 kg of food (ANA 0.5). Anastrozole-treated animals did not show macroscopic changes in the uterus or vagina, and the absolute and relative wet weights of the uterus and vagina were comparable to controls in both ANA 0.05 and ANA 0.5 groups. Histological examination revealed no atrophic changes in the endometrium of the uterus or epithelium of the vagina in anastrozole-treated animals. However, the myometrium was significantly thicker in the ANA 0.5 group compared to the ANA 0.05 group (P<0.05). Anastrozole did not affect plasma lipid metabolism parameters (triacylglycerols, total cholesterol, LDL cholesterol, and HDL cholesterol) or serum levels of sex hormones (estradiol, testosterone, dehydroepiandrosterone). Compact bone thickness was significantly increased in anastrozole-treated animals compared to untreated animals (P<0.001). The ANA 0.5 group had a significant increase in body weight compared to the control group (P<0.01), but this increase was not accompanied by a significant increase in food intake. In conclusion, the side effects of anastrozole in this model were observed in the myometrium, compact bone thickness, and body weight gain.
Paper Details　
Original Abstract of the Article :
The aim of this study was to assess side effects of aromatase inhibitor anastrozole in the prevention of N-methyl-N-nitrosourea - induced pre-menopausal mammary carcinogenesis in female Sprague-Dawley rats. This model mimicked situation in healthy, but from the point of view of the development of br...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4149/neo_2009_02_124

データ提供：米国国立医学図書館（NLM）

Anastrozole: A Powerful Weapon Against Breast Cancer with Potential Side Effects

The field of cancer prevention is constantly seeking new ways to reduce the risk of developing cancer. This study investigated the side effects of anastrozole, an aromatase inhibitor, in preventing breast cancer in premenopausal female rats. The researchers found that anastrozole treatment resulted in increased myometrial thickness, increased bone density, and increased body weight gain. However, anastrozole did not affect plasma lipid metabolism or serum levels of sex hormones.

Balancing Benefits and Risks: A Careful Assessment of Anastrozole

This study highlights the importance of carefully weighing the potential benefits and risks of cancer prevention strategies. Anastrozole has shown promise in preventing breast cancer, but it can also have significant side effects. The researchers observed increased myometrial thickness, increased bone density, and increased body weight gain in rats treated with anastrozole.

A Personalized Approach to Cancer Prevention: Tailoring Treatment Strategies

This research underscores the need for a personalized approach to cancer prevention. The side effects of anastrozole can vary significantly among individuals, and it is crucial to consider these factors when recommending this medication. Healthcare providers should carefully assess individual patient characteristics and risk factors to determine the most appropriate course of action.

Dr.Camel's Conclusion

This study provides valuable insights into the potential side effects of anastrozole, an aromatase inhibitor used for breast cancer prevention. The observed effects on myometrial thickness, bone density, and body weight highlight the importance of careful monitoring and individualized treatment decisions. Further research is needed to better understand the long-term implications of anastrozole therapy and to develop strategies for mitigating potential side effects.

Date :
  1. Date Completed 2009-05-19
  2. Date Revised 2019-11-11
Further Info :

Pubmed ID

19239326

DOI: Digital Object Identifier

10.4149/neo_2009_02_124

Related Literature

Article Analysis
・Side Effects of anastrozole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.